Cardiovascular risk in subjects with high probability of metabolic syndrome and insulin resistance: DESIRE study;Riesgo cardiovascular en sujetos con alta probabilidad de síndrome metabólico y resistencia a la insulina. Estudio DESIRE

Revista Clinica Espanola

Volumn 208, Issue 8, 2008, Pages 377-385

  Goday Arno, A ^a,f   Gabriel, R ^b   Ascaso, J F ^c   Franch, J ^d   Ortega, R ^e   Martinez O ^e   Lerones, N ^e  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d Sant Feliu de Llobregat   (Spain)

^e GLAXOSMITHKLINE   (Spain)

^f HOSPITAL DEL MAR   (Spain)

Author keywords

Cardiovascular risk; Insulin resistance; Metabolic syndrome

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CENTER; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PROBABILITY; SCORING SYSTEM; SPAIN; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 59449090810     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1157/13126339     Document Type: Article

References (33)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation. 2005;112:1-18.
2. Reaven G. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
3. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-22.
4. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small dense LDL) in men? Circulation. 2000;102:179-84.
5. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087-94.
6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
7. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;5:469-80.
8. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288:2709-16.
9. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-9.
10. Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinky Policemen Study. Arterioscler Thromb Vasc Biol. 2000;20:538-44.
11. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ. 2006;332:878-82.
12. Levantesi G, Macchia A, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol. 2005;46:277-83.
13. Lorenzo C, Okoloise M, Williams K, Stern M, Haffner S. The metabolic syndrome a predictor of type 2 diabetes. The San Antonio Heart Study. Diabetes Care. 2003;26:3153-9.
14. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications study. Diabet Med. 2003;21:52-8.
15. Gimeno Orna JA, Lou Arnal LM, Molinero Herguedas E, Boned Julián B, Portilla Córdoba DP. Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2. Rev Esp Cardiol. 2004;57:507-13.
16. Laakso M. Insulin resistance and its impact on the approach to therapy of type 2 diabetes. Int J Clin Pract Suppl. 2001;(121):8-12.
17. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25:1880-90.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
19. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organization; 1999.
20. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing Insulin Resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320-5.
21. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-45.
22. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
23. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;11:987-1003.
24. Tormo Díaz MJ, Dal-Ré R, Pérez Albarracín G. Ética e investigación epidemiológica: principios, aplicaciones y casos prácticos. Murcia: Sociedad Española de Epidemiología; 1998.
25. International guidelines for ethical review of epidemiological studies. Geneva: Council of International Organizations of Medical Sciences; 1991.
26. García-Puig J, Ruilope LM, Luque M, Fernández J, Ortega R, Dal-Ré R on behalf of the AVANT Study Group Investigators. Glucose metabolism alterations in patients with essential hypertension. Am J Med. 2006;119:318-26.
27. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843-8.
28. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49:2112-9.
29. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-105.
30. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens. 2003;16:41S-5S.
31. Martínez-Larrad MT, Fernández-Pérez C, González-Sánchez JL, López A, Fernández- Álvarez J, Riviriego J, et al. Prevalencia del síndrome metabólico (criterios ATP-III). Estudio de base poblacional en áreas rural y urbana de la provincia de Segovia. Med Clin (Barc). 2005;125: 481-6.
32. Athyros VG, Bouloukos VI, Pehlivanidis AN, Papageorgiou AA, Dionysopoulou SG, Symeonidis AN, et al. MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab. 2005;7:397-405.
33. Qiao Q, DECODE Study Group. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia. 2006;49:2837-46.